Market Closed -
TEL AVIV STOCK EXCHANGE
10:24:26 2024-07-02 EDT
|
5-day change
|
1st Jan Change
|
38
ILa
|
0.00%
|
|
0.00%
|
-43.28%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
54.36
|
40.94
|
64.56
|
36.92
|
14.37
|
7.429
|
Enterprise Value (EV)
1 |
36.37
|
37.88
|
30.05
|
13
|
1.44
|
0.9693
|
P/E ratio
|
-172
x
|
-1.84
x
|
2.06
x
|
1.3
x
|
-0.46
x
|
-0.25
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
217
x
|
1,780
x
|
-
|
-
|
-
|
-
|
EV / Revenue
|
145
x
|
1,647
x
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-13
x
|
-10.8
x
|
-22.9
x
|
-6.25
x
|
-0.53
x
|
-0.55
x
|
EV / FCF
|
-12.4
x
|
60.1
x
|
-8.54
x
|
-7.72
x
|
-1.23
x
|
-0.68
x
|
FCF Yield
|
-8.06%
|
1.66%
|
-11.7%
|
-12.9%
|
-81%
|
-148%
|
Price to Book
|
1.59
x
|
7.52
x
|
1.74
x
|
0.56
x
|
0.41
x
|
1.25
x
|
Nbr of stocks (in thousands)
|
11,053
|
11,053
|
11,089
|
11,089
|
11,089
|
11,089
|
Reference price
2 |
4.918
|
3.704
|
5.822
|
3.330
|
1.296
|
0.6700
|
Announcement Date
|
3/28/19
|
4/30/20
|
3/25/21
|
3/24/22
|
3/28/23
|
3/12/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.25
|
0.023
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-2.796
|
-3.499
|
-1.312
|
-2.079
|
-2.729
|
-1.778
|
EBIT
1 |
-3.043
|
-3.506
|
-1.32
|
-2.083
|
-2.732
|
-1.781
|
Operating Margin
|
-1,217.2%
|
-15,243.48%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-4.128
|
-22.3
|
31.22
|
28.36
|
-31.21
|
-29.19
|
Net income
1 |
-0.316
|
-22.3
|
31.21
|
28.36
|
-31.21
|
-29.19
|
Net margin
|
-126.4%
|
-96,934.78%
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0286
|
-2.017
|
2.820
|
2.558
|
-2.815
|
-2.632
|
Free Cash Flow
1 |
-2.931
|
0.63
|
-3.516
|
-1.683
|
-1.166
|
-1.432
|
FCF margin
|
-1,172.45%
|
2,739.13%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/19
|
4/30/20
|
3/25/21
|
3/24/22
|
3/28/23
|
3/12/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
18
|
3.06
|
34.5
|
23.9
|
12.9
|
6.46
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-2.93
|
0.63
|
-3.52
|
-1.68
|
-1.17
|
-1.43
|
ROE (net income / shareholders' equity)
|
-8.9%
|
-112%
|
147%
|
55.2%
|
-61.9%
|
-142%
|
ROA (Net income/ Total Assets)
|
-3.66%
|
-9.79%
|
-3.25%
|
-2.42%
|
-3.24%
|
-4.73%
|
Assets
1 |
8.635
|
227.6
|
-960.7
|
-1,174
|
963
|
616.4
|
Book Value Per Share
2 |
3.100
|
0.4900
|
3.340
|
5.920
|
3.160
|
0.5400
|
Cash Flow per Share
2 |
1.490
|
0.1800
|
0.4500
|
0.2500
|
0.0700
|
0.0400
|
Capex
1 |
0.46
|
0.01
|
0
|
0.01
|
-
|
-
|
Capex / Sales
|
185.2%
|
21.74%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/19
|
4/30/20
|
3/25/21
|
3/24/22
|
3/28/23
|
3/12/24
|
|
1st Jan change
|
Capi.
|
---|
| -43.28% | 1.12M | | +17.72% | 44.44B | | -10.33% | 37.99B | | +37.55% | 37.75B | | +29.36% | 30.78B | | -8.44% | 27.38B | | +12.45% | 26.17B | | +44.19% | 14.15B | | +31.93% | 12.59B | | -7.67% | 11.28B |
Other Biotechnology & Medical Research
|